Maria Trojano

List of Publications by Year
in descending order

409 papers	25,470 citations	9264 74 h-index	10158 140 g-index
427 all docs	427 docs citations	427 times ranked	18705 citing authors

#	Article	IF	Citations
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
2	Multiple Sclerosis Severity Score. Neurology, 2005, 64, 1144-1151.	1.1	836
3	Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.. Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 897-902.	1.9	589
4	The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 305-317.	3.0	381
5	Diseaseâ€Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Annals of Neurology, 2021, 89, 780-789.	5.3	370
6	The Raoâ€™s Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Multiple Sclerosis Journal, 2006, 12, 787-793.	3.0	343
7	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
8	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
9	The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921.	1.1	274
10	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281.	3.0	273
11	Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology, 1997, 244, 153-159.	3.6	257
12	New natural history of interferon-Î²-treated relapsing multiple sclerosis. Annals of Neurology, 2007, 61, 300-306.	5.3	251
13	Cognitive and psychosocial features of childhood and juvenile MS. Neurology, 2008, 70, 1891-1897.	1.1	251
14	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
15	Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica. Journal of Neurology, 2004, 251, 47-52.	3.6	246
16	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238
17	Neuropsychological features in childhood and juvenile multiple sclerosis. Neurology, 2014, 83, 1432-1438.	1.1	227
18	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	10.2	219

#	Article	IF	Citations
19	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Multiple Sclerosis Journal, 2017, 23, 1258-1267.	3.0	209
20	Cognitive and psychosocial features in childhood and juvenile MS. Neurology, 2010, 75, 1134-1140.	1.1	198
21	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. Sleep, 2008, 31, 944-952.	1.1	175
22	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Multiple Sclerosis Journal, 2009, 15, 779-788.	3.0	172
23	MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 769-774.	3.0	168
24	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	2.5	166
25	Age-related disability in multiple sclerosis. Annals of Neurology, 2002, 51, 475-480.	5.3	163
26	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162
27	Predictors of long–term disability accrual in relapse–onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
28	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	1.9	156
29	Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. Journal of Neuroimmunology, 2003, 136, 46-53.	2.3	154
30	Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nature Reviews Neurology, 2017, 13, 105-118.	10.1	154
31	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	3.0	148
32	Benign multiple sclerosis. Journal of Neurology, 2006, 253, 1054-1059.	3.6	147
33	Aquaporin–4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia, 2009, 57, 1363-1373.	4.9	143
34	Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
35	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. Journal of Neurology, 2004, 251, 1208-1214.	3.6	142
36	Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802.	1.1	142

#	Article	IF	Citations
37	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	7.6	140
38	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
39	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.1	138
40	Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150.	1.1	135
41	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
42	Realâ€life impact of early interferonβ therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	5.3	132
43	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293.	3.0	131
44	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 318-331.	3.0	131
45	Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS. Neurology, 1999, 53, 1402-1402.	1.1	125
46	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS ONE, 2015, 10, e0122686.	2.5	122
47	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 77-87.	3.0	119
48	Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events.. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 300-306.	1.9	113
49	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
50	Anxiety and depression in multiple sclerosis patients around diagnosis. Journal of the Neurological Sciences, 2011, 307, 86-91.	0.6	105
51	Subclinical Visual Involvement in Multiple Sclerosis: A Study by MRI, VEPs, Frequency-Doubling Perimetry, Standard Perimetry, and Contrast Sensitivity. , 2005, 46, 1264.		104
52	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. Multiple Sclerosis Journal, 2014, 20, 91-98.	3.0	103
53	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e823-e831.	1.1	102
54	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603.	3.0	101

#	Article	IF	Citations
55	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
56	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 342-349.	3.0	100
57	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Multiple Sclerosis Journal, 2005, 11, 420-424.	3.0	99
58	The brief international cognitive assessment for multiple sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. BMC Neurology, 2014, 14, 171.	1.8	99
59	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.1	98
60	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 660-668.	1.9	97
61	Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Multiple Sclerosis Journal, 2002, 8, 222-228.	3.0	96
62	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
63	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
64	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 68-77.	3.0	89
65	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 944-951.	1.9	88
66	Neurofilament ELISA validation. Journal of Immunological Methods, 2010, 352, 23-31.	1.4	86
67	DMTs and Covidâ€‑19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
68	Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2014, 2, 84.	5.2	85
69	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	1.8	82
70	Impact of Natalizumab on Cognitive Performances and Fatigue in Relapsing Multiple Sclerosis: A Prospective, Open-Label, Two Years Observational Study. PLoS ONE, 2012, 7, e35843.	2.5	82
71	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. Journal of Neurology, 2002, 249, 152-163.	3.6	81
72	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 294-304.	3.0	79

#	Article	IF	Citations
73	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	3.0	79
74	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Multiple Sclerosis Journal, 2005, 11, 441-446.	3.0	78
75	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. Multiple Sclerosis Journal, 2007, 13, 412-419.	3.0	78
76	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	1.8	78
77	Communicating the diagnosis of multiple sclerosis - a qualitative study. Multiple Sclerosis Journal, 2007, 13, 763-769.	3.0	77
78	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 329-334.	3.0	77
79	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain, 2015, 138, 3275-3286.	7.6	76
80	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1133-1137.	1.9	76
81	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab. Neurology, 2018, 90, e832-e839.	1.1	74
82	High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. Journal of the Neurological Sciences, 1996, 144, 182-190.	0.6	73
83	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	3.0	73
84	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	3.0	72
85	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
86	A genome screen for multiple sclerosis in Italian families. Genes and Immunity, 2001, 2, 205-210.	4.1	70
87	Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. Glia, 2017, 65, 790-803.	4.9	70
88	Pregnancy, sex and hormonal factors in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 527-536.	3.0	69
89	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	1.9	68
90	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895.	1.1	68

#	Article	IF	Citations
91	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. Annals of Neurology, 2014, 76, 880-890.	5.3	67
92	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. Journal of Neuroimmunology, 2005, 163, 172-178.	2.3	66
93	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	1.9	66
94	Age at onset in multiple sclerosis. Neurological Sciences, 2000, 21, S825-S829.	1.9	65
95	Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Multiple Sclerosis Journal, 2003, 9, 451-457.	3.0	65
96	Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Human Molecular Genetics, 2018, 27, 66-79.	2.9	65
97	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Multiple Sclerosis Journal, 2010, 16, 1393-1405.	3.0	64
98	Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 2016, 86, 1446-1453.	1.1	64
99	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
100	The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. Neurological Sciences, 2001, 22, S98-S102.	1.9	62
101	Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion. Clinical Chemistry and Laboratory Medicine, 2003, 41, 331-7.	2.3	62
102	Post-receptorial mechanisms underlie functional disregulation of Î²2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. Journal of Neuroimmunology, 2004, 155, 143-149.	2.3	59
103	Identification of Two Major Conformational Aquaporin-4 Epitopes for Neuromyelitis Optica Autoantibody Binding. Journal of Biological Chemistry, 2011, 286, 9216-9224.	3.4	59
104	The Italian multiple sclerosis register. Neurological Sciences, 2019, 40, 155-165.	1.9	59
105	Multiple sclerosis registries in Europe â€" results of a systematic survey. Multiple Sclerosis Journal, 2014, 20, 1523-1532.	3.0	58
106	Dopamine Fails to Regulate Activation of Peripheral Blood Lymphocytes from Multiple Sclerosis Patients: Effects of IFN-Î². Journal of Interferon and Cytokine Research, 2005, 25, 395-406.	1.2	57
107	Treatment of early-onset multiple sclerosis with intramuscular interferonÎ²-1a: long-term results. Neurological Sciences, 2007, 28, 127-132.	1.9	57
108	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	3.7	57

#	Article	IF	Citations
109	COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	57
110	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 620-626.	3.0	56
111	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 2012, 18, 974-982.	3.0	56
112	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Multiple Sclerosis Journal, 2013, 19, 1106-1112.	3.0	56
113	Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?. Clinical Neurology and Neurosurgery, 2021, 208, 106887.	1.4	56
114	Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep, 2008, 31, 944-52.	1.1	56
115	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 757-759.	1.9	55
116	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Multiple Sclerosis Journal, 2020, 26, 23-37.	3.0	55
117	Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. Journal of the Neurological Sciences, 2005, 239, 95-99.	0.6	54
118	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54
119	Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. Neurobiology of Disease, 2011, 43, 678-689.	4.4	53
120	Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study. PLoS ONE, 2013, 8, e74111.	2.5	53
121	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. Brain, 2020, 143, 3013-3024.	7.6	53
122	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
123	Anxiety state affects information processing speed in patients with multiple sclerosis. Neurological Sciences, 2014, 35, 559-563.	1.9	51
124	Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. Journal of Neurology, 1985, 231, 336-339.	3.6	50
125	A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year. Canadian Journal of Neurological Sciences, 1994, 21, 266-270.	0.5	50
126	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Multiple Sclerosis Journal, 2010, 16, 100-111.	3.0	50

#	Article	IF	Citations
127	Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab. JAMA Neurology, 2014, 71, 954.	9.0	50
128	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
129	Glatiramer Acetate in Multiple Sclerosis: A Review. CNS Neuroscience & Therapeutics, 2007, 13, 178-191.	4.0	48
130	The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology, 2016, 86, 1437-1445.	1.1	48
131	Immunomodulatory therapies delay disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1732-1740.	3.0	48
132	AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding. Acta Neuropathologica Communications, 2019, 7, 51.	5.2	48
133	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	48
134	Multiple sclerosis registries in Europe – An updated mapping survey. Multiple Sclerosis and Related Disorders, 2019, 27, 171-178.	2.0	47
135	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
136	Genetic interaction of <i>CTLA-4</i> with HLA-DR15 in multiple sclerosis patients. Annals of Neurology, 2003, 54, 119-122.	5.3	46
137	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. Neurological Sciences, 2013, 34, 2085-2093.	1.9	46
138	Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RICe). Frontiers in Neurology, 2020, 11, 597881.	2.4	45
139	Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive	3.0	43
140	Dopaminergic Modulation of CD4+CD25high Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-ß Therapy. NeuroImmunoModulation, 2012, 19, 283-292.	1.8	43
141	The impact of neutralizing antibodies on the risk of disease worsening in interferon β–treated relapsing multiple sclerosis: a 5 year post-marketing study. Journal of Neurology, 2013, 260, 1562-1568.	3.6	43
142	Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology, 2015, 2, 479-491.	3.7	43
143	Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurologica Scandinavica, 2015, 131, 336-340.	2.1	43
144	Intrathecal IgG synthesis in multiple sclerosis: Comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG. Journal of Neurology, 1981, 224, 159-169.	3.6	42

#	Article	IF	Citations
145	Psychosocial issue in children and adolescents with multiple sclerosis. Neurological Sciences, 2010, 31, 467-470.	1.9	42
146	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517.	3.0	42
147	Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis. Neurology, 1996, 47, 1535-1541.	1.1	40
148	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. Journal of Neurology, 2003, 250, 1094-1098.	3.6	40
149	European validation of a standardized clinical description of multiple sclerosis. Journal of Neurology, 2004, 251, 1472-1480.	3.6	40
150	Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. European Neurology, 2016, 76, 216-226.	1.4	40
151	Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. International Journal of Molecular Sciences, 2018, 19, 3652.	4.1	40
152	Variations of the perforin gene in patients with multiple sclerosis. Genes and Immunity, 2008, 9, 438-444.	4.1	39
153	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341.	3.0	39
154	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. Journal of Clinical Psychology in Medical Settings, 2016, 23, 33-52.	1.4	39
155	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
156	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. Journal of Neurology, 2022, 269, 1670-1677.	3.6	39
157	observational studies: propensity score analysis of non-randomized data. International MS Journal, 2009, 16, 90-7.	0.3	39
158	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. European Journal of Human Genetics, 1999, 7, 377-385.	2.8	38
159	Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. PLoS ONE, 2013, 8, e79185.	2.5	38
160	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
161	Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain, 2022, 145, 2796-2805.	7.6	38
162	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	1.9	37

#	Article	IF	Citations
163	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. Journal of the Neurological Sciences, 2014, 337, 67-73.	0.6	37
164	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
165	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
166	ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon Î²-1a and TNFÎ±. Journal of Neuroimmunology, 1998, 88, 13-20.	2.3	36
167	The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. Brain, Behavior, and Immunity, 2014, 35, 176-181.	4.1	36
168	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
169	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	3.0	36
170	Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. Journal of the Neurological Sciences, 2020, 416, 117011.	0.6	36
171	Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. Journal of Neurology, 2012, 259, 2105-2110.	3.6	35
172	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.6	35
173	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
174	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	2.5	35
175	Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Human Immunology, 2003, 64, 274-284.	2.4	34
176	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	3.0	34
177	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
178	Multiple sclerosis in Italy: cost-of-illness study. Neurological Sciences, 2011, 32, 787-794.	1.9	33
179	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
180	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. PLoS ONE, 2019, 14, e0213508.	2.5	33

#	Article	IF	Citations
181	A Pattern of Cognitive Deficits Stratified for Genetic and Environmental Risk Reliably Classifies Patients With Schizophrenia From Healthy Control Subjects. Biological Psychiatry, 2020, 87, 697-707.	1.3	33
182	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555.	3.0	33
183	Natural History of Multiple Sclerosis: Have Available Therapies Impacted Long-Term Prognosis?. Neurologic Clinics, 2011, 29, 309-321.	1.8	32
184	Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients. Current Neurovascular Research, 2012, 9, 120-127.	1.1	32
185	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 2015, 22, 981-989.	3.3	32
186	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1741-1749.	3.0	32
187	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
188	Early use of high-efficacy diseaseâ€‘modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. Journal of Neurology, 2022, 269, 5382-5394.	3.6	32
189	Safety profile of Tysabri: international risk management plan. Neurological Sciences, 2009, 30, 159-162.	1.9	31
190	Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. Neuropathology and Applied Neurobiology, 2013, 39, 736-749.	3.2	31
191	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. BMC Neurology, 2015, 15, 204.	1.8	31
192	Autophagy markers LC3 and p62 accumulate in immuneâ€‘mediated necrotizing myopathy. Muscle and Nerve, 2019, 60, 315-327.	2.2	31
193	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. SSRN Electronic Journal, 0, , .	0.4	31
194	Risk of Getting COVID-19 in People With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	31
195	Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta. Brain Research Bulletin, 2003, 61, 357-364.	3.0	30
196	Proteomic Profiling in Multiple Sclerosis Clinical Courses Reveals Potential Biomarkers of Neurodegeneration. PLoS ONE, 2014, 9, e103984.	2.5	30
197	Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurological Sciences, 2014, 35, 307-316.	1.9	30
198	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30

#	Article	IF	Citations
199	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. Neurological Sciences, 2017, 38, 1849-1858.	1.9	30
200	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642092268.	3.5	30
201	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. Journal of Neuroimmunology, 2006, 179, 108-116.	2.3	29
202	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1355-1359.	1.9	29
203	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
204	The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurological Sciences, 2003, 24, s268-s270.	1.9	28
205	Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. Journal of Neuroimmunology, 2012, 245, 93-97.	2.3	28
206	A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2240-2253.	3.0	28
207	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics: Targets and Therapy, 2009, 3, 369-76.	3.2	28
208	CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. Journal of Neuroimmunology, 2003, 140, 216-221.	2.3	27
209	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. Journal of the Neurological Sciences, 2004, 223, 69-71.	0.6	27
210	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 578-585.	3.0	27
211	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	1.8	27
212	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1297-1303.	1.9	27
213	Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. Journal of Neuroimmunology, 2008, 197, 140-146.	2.3	26
214	Age-related changes of serum N-acetyl-aspartate in healthy controls. Age and Ageing, 2011, 40, 391-395.	1.6	26
215	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480.	2.5	26
216	Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. Brain and Behavior, 2019, 9, e01199.	2.2	26

#	Article	IF	Citations
217	Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. Journal of Neurology, 2007, 254, 597-604.	3.6	25
218	Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceutics. Antioxidants, 2021, 10, 21.	5.1	25
219	Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. Journal of the Neurological Sciences, 1984, 64, 245-258.	0.6	24
220	Atypical forms of multiple sclerosis or different phases of a same disease?. Neurological Sciences, 2004, 25, s323-s325.	1.9	24
221	Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?. Neurology, 2007, 69, 1478-1479.	1.1	24
222	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon Î²1b therapy in relapsingâ€"remitting multiple sclerosis (the ARIANNA study). Multiple Sclerosis Journal, 2016, 22, 1163-1173.	3.0	24
223	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
224	Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment. Journal of the Neurological Sciences, 2009, 286, 109-113.	0.6	23
225	Serum levels of N-acetyl-aspartate in migraine and tension-type headache. Journal of Headache and Pain, 2012, 13, 389-394.	6.0	23
226	Longâ€term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study. Journal of Clinical Pharmacology, 2015, 55, 1131-1136.	2.0	23
227	Gender differences in safety issues during Fingolimod therapy: Evidence from a realâ€life Relapsing Multiple Sclerosis cohort. Brain and Behavior, 2017, 7, e00804.	2.2	22
228	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	22
229	IFN-<i>Î²</i>1a Modulates the Expression of CTLA-4 and CD28 Splice Variants in Human Mononuclear Cells: Induction of Soluble Isoforms. Journal of Interferon and Cytokine Research, 2001, 21, 809-812.	1.2	21
230	Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, Î²-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes. Cellular Signalling, 2002, 14, 673-678.	3.6	21
231	Glatiramer acetate induces proâ€"apoptotic mechanisms involving Bclâ€"2, Bax and Cytâ€"c in peripheral lymphocytes from multiple sclerosis patients. Journal of Neurology, 2006, 253, 231-236.	3.6	21
232	Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients. PLoS ONE, 2012, 7, e40608.	2.5	21
233	Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple. Journal of the Neurological Sciences, 2013, 324, 100-105.	0.6	21
234	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 2016, 23, 729-736.	3.3	21

#	Article	IF	Citations
235	Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. Journal of Neurology, 2016, 263, 1620-1625.	3.6	21
236	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2020, 77, 1398.	9.0	21
237	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
238	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
239	Interferon β-1a downregulates TNFα-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. Brain Research, 2000, 881, 227-230.	2.2	20
240	Differential Regulation of Membrane Bound and Soluble ICAM 1 in Human Endothelium and Blood Mononuclear Cells: Effects of Interferon Beta-1a. Cell Communication and Adhesion, 2002, 9, 259-272.	1.0	20
241	Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. Journal of Neurology, 2004, 251, 165-170.	3.6	20
242	Italian studies on early-onset multiple sclerosis: the present and the future. Neurological Sciences, 2004, 25, s346-s349.	1.9	20
243	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. Genes and Immunity, 2008, 9, 7-15.	4.1	20
244	Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study. European Neurology, 2015, 74, 178-185.	1.4	20
245	Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 396-401.	3.0	20
246	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. Multiple Sclerosis Journal, 2016, 22, 18-33.	3.0	20
247	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	9.0	20
248	Italian consensus on treatment of spasticity in multiple sclerosis. European Journal of Neurology, 2020, 27, 445-453.	3.3	20
249	Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. Multiple Sclerosis Journal, 1998, 4, 39-44.	3.0	19
250	Inhibition of protein kinase C counteracts TNFα-induced intercellular adhesion molecule 1 expression and fluid phase endocytosis on brain microvascular endothelial cells. Brain Research, 2000, 863, 245-248.	2.2	19
251	Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1153-1160.	3.0	19
252	Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. Journal of Clinical Pharmacology, 2016, 56, 845-851.	2.0	19

#	Article	IF	Citations
253	Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1039-1045.	3.0	19
254	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Multiple Sclerosis Journal, 2021, 27, 430-438.	3.0	19
255	Italian Multiple Sclerosis Database Network. Neurological Sciences, 2006, 27, s358-s361.	1.9	18
256	Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients. Journal of Neuroimmunology, 2017, 303, 75-80.	2.3	18
257	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
258	Tissue Distribution of the Readthrough Isoform of AQP4 Reveals a Dual Role of AQP4ex Limited to CNS. International Journal of Molecular Sciences, 2020, 21, 1531.	4.1	18
259	A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. Journal of Neuroimmunology, 2003, 143, 97-100.	2.3	17
260	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	1.9	17
261	Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. Journal of the Neurological Sciences, 2013, 330, 56-60.	0.6	17
262	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	2.0	17
263	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. Disability and Rehabilitation, 2020, 42, 3780-3792.	1.8	17
264	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological wellâ€being. Health and Social Care in the Community, 2020, 28, 236-246.	1.6	17
265	PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels. Biomedicines, 2020, 8, 85.	3.2	17
266	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. Journal of Clinical Psychology in Medical Settings, 2021, 28, 149-160.	1.4	17
267	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology, 2021, 12, 647811.	2.4	17
268	Firstâ€line therapies in lateâ€onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	3.3	17
269	Serum IgG to brain microvascular endothelial cells in multiple sclerosis. Journal of the Neurological Sciences, 1996, 143, 107-113.	0.6	16
270	Treating multiple sclerosis with natalizumab. Expert Review of Neurotherapeutics, 2011, 11, 1683-1692.	2.8	16

#	Article	IF	Citations
271	History of multiple sclerosis in 2 successive pregnancies. Neurology, 2016, 87, 1360-1367.	1.1	16
272	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open, 2017, 7, e017254.	1.9	16
273	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
274	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurological Sciences, 2020, 41, 3185-3193.	1.9	15
275	Real-world disability improvement in patients with relapsingâ€"remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal, 2021, 27, 719-728.	3.0	15
276	A Case Report of Double Filtration Plasmapheresis in an Acute Episode of Multiple Sclerosis. Therapeutic Apheresis and Dialysis, 2008, 12, 250-254.	0.9	14
277	Implementation of the â€˜Sapere Miglioraâ€™ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. Multiple Sclerosis Journal, 2014, 20, 1234-1243.	3.0	14
278	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
279	Supramolecular aggregation of aquaporinâ€4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. Journal of Cellular and Molecular Medicine, 2018, 22, 1236-1246.	3.6	14
280	Comparison of clinical and demographic features between affected pairs of Italian Multiple Sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. Journal of the Neurological Sciences, 1999, 162, 194-200.	0.6	13
281	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery, 2016, 13, 799-805.	5.0	13
282	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.0	13
283	Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2020, 34, 65-92.	5.9	13
284	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	3.0	13
285	Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFNÎ²-1b treatment. Multiple Sclerosis Journal, 1998, 4, 183-187.	3.0	12
286	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. Journal of Neuroimmunology, 2003, 143, 31-38.	2.3	12
287	Antiâ€inflammatory diseaseâ€modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. European Journal of Neurology, 2019, 26, 363-370.	3.3	12
288	Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsingâ€"remitting multiple sclerosis: 2-year results from the COGIMUS study. Therapeutic Advances in Neurological Disorders, 2009, 2, 67-77.	3.5	11

#	Article	IF	Citations
289	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurology, 2011, 11, 125.	1.8	11
290	Emotional and neutral verbal memory impairment in Multiple Sclerosis. Journal of the Neurological Sciences, 2014, 341, 28-31.	0.6	11
291	Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort. Frontiers in Immunology, 2019, 10, 1343.	4.8	11
292	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
293	Isoelectric focusing and quantitative estimation of cerebrospinal fluid and serum IgG in idiopathic polyneuropathy. Journal of Neurology, 1980, 223, 1-12.	3.6	10
294	Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica, 2013, 127, 301-308.	2.1	10
295	Age-related Vascular Differences among Patients Suffering from Multiple Sclerosis. Current Neurovascular Research, 2014, 11, 23-30.	1.1	10
296	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. Annals of Neurology, 2018, 84, 958-959.	5.3	10
297	Magnetoencephalography and High-Density Electroencephalography Study of Acoustic Event Related Potentials in Early Stage of Multiple Sclerosis: A Pilot Study on Cognitive Impairment and Fatigue. Brain Sciences, 2021, 11, 481.	2.3	10
298	Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive	1.1	
299	Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. Neurology, 2013, 81, 1470-1471.	1.1	9
300	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	4.4	9
301	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110424.	3.5	9
302	Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. Multiple Sclerosis Journal, 1998, 4, 39-44.	3.0	9
303	Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy. Rheumatology, 2022, 61, 3448-3460.	1.9	9
304	Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. European Cytokine Network, 2003, 14, 154-7.	2.0	9
305	Alteration of the translational readthrough isoform AQP4ex induces redistribution and downregulation of AQP4 in human glioblastoma. Cellular and Molecular Life Sciences, 2022, 79, 140.	5.4	9
306	Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 787160.	2.4	9

#	Article	IF	Citations
307	Immunomodulatory properties of increased levels of liver X receptor β in peripheral blood mononuclear cells from multiple sclerosis patients. Experimental Neurology, 2007, 204, 759-766.	4.1	8
308	The evolving diagnostic criteria for multiple sclerosis. Nature Reviews Neurology, 2011, 7, 251-252.	10.1	8
309	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	2.5	8
310	Progress in multiple sclerosis â€" from diagnosis to therapy. Nature Reviews Neurology, 2018, 14, 72-74.	10.1	8
311	Silent lesions on MRI imaging â€" Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	3.0	8
312	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463.	3.0	8
313	A case report of lateâ€onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. Brain and Behavior, 2021, 11, e01930.	2.2	8
314	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. Journal of Medical Internet Research, 2021, 23, e29558.	4.3	8
315	The effectiveness of natalizumab vs fingolimodâ€"A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
316	Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. Neurological Sciences, 2022, 43, 1903-1910.	1.9	8
317	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
318	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
319	Can databasing optimise patient care?. Journal of Neurology, 2004, 251, v79-v82.	3.6	7
320	Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. PLoS ONE, 2015, 10, e0143679.	2.5	7
321	The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. European Journal of Clinical Pharmacology, 2016, 72, 1025-1029.	1.9	7
322	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	6.0	7
323	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. Neurological Sciences, 2020, 41, 2843-2851.	1.9	7
324	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP). Multiple Sclerosis Journal, 2021, 27, 410-419.	3.0	7

#	Article	IF	Citations
325	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis Journal, 2021, 27, 479-482.	3.0	7
326	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
327	Isoelectric focusing and crossed immunoelectrofocusing of cerebrospinal fluid proteins in neurological disorders. Acta Neurologica, 1978, 33, 501-17.	0.1	7
328	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. Neurology, 2022, 98, e1626-e1636.	1.1	7
329	Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres. Journal of Immunoassay and Immunochemistry, 2008, 30, 40-50.	1.1	6
330	First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients. Clinical and Experimental Medicine, 2016, 16, 103-107.	3.6	6
331	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
332	Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy. Brain Sciences, 2020, 10, 548.	2.3	6
333	Detection of disability worsening in relapsing–remitting multiple sclerosis patients: a real–world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. European Journal of Neurology, 2021, 28, 567-578.	3.3	6
334	Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years. Neurological Sciences, 2021, 42, 4647-4655.	1.9	6
335	Comparing natural history of early and late onset pediatric multiple sclerosis. Annals of Neurology, 2022, , .	5.3	6
336	LFA-1 expression on CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNβ-1a. Journal of the Neurological Sciences, 2001, 186, 65-73.	0.6	5
337	The IFNβ treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. Neurological Sciences, 2005, 26, s179-s182.	1.9	5
338	The MoSt Project——More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. Journal of Neurology, 2014, 261, 526-532.	3.6	5
339	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2015, 1, 205521731560019.	1.0	5
340	DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient. Stem Cell Research and Therapy, 2019, 10, 29.	5.5	5
341	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	2.5	5
342	Interrogating large multiple sclerosis registries and databases: what information can be gained?. Current Opinion in Neurology, 2022, 35, 271-277.	3.6	5

#	Article	IF	Citations
343	Adrenergic mechanisms in multiple sclerosis: the neuro–immune connection?. Trends in Pharmacological Sciences, 2004, 25, 350-351.	8.7	4
344	Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role?. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 469-469.	1.9	4
345	Serum levels of N-acetylaspartate in Huntington's disease: Preliminary results. Movement Disorders, 2012, 27, 329-330.	3.9	4
346	Complexity of MS management in the current treatment era. Neurology, 2018, 90, 761-762.	1.1	4
347	Natalizumab reduces serum pro-angiogenic activity in MS patients. Neurological Sciences, 2018, 39, 725-731.	1.9	4
348	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. Journal of Neurology, 2021, 268, 1540-1543.	3.6	4
349	Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method. Frontiers in Neurology, 2021, 12, 633115.	2.4	4
350	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Journal of Neurology, 2022, 269, 1463-1469.	3.6	4
351	The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy. PLoS ONE, 2016, 11, e0159214.	2.5	4
352	Perampanel during pregnancy: Description of four cases. Epilepsy and Behavior Reports, 2021, 16, 100490.	1.0	4
353	Postmarketing evidence of disease-modifying drugs in multiple sclerosis. Neurological Sciences, 2008, 29, 225-226.	1.9	3
354	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics: Targets and Therapy, 0, , 369.	3.2	3
355	COGNITIVE AND PSYCHOSOCIAL FEATURES OF CHILDHOOD AND JUVENILE MS. Neurology, 2009, 72, 1189-1190.	1.1	3
356	MS and related disorders: looking for markers of phenotypes. Lancet Neurology, The, 2015, 14, 11-13.	10.2	3
357	Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles–New Insights for Structural and Functional Studies. Cells, 2019, 8, 119.	4.1	3
358	Durvalumab and multiple sclerosis: a causal link or simple unmasking?. European Journal of Clinical Pharmacology, 2020, 76, 1773-1774.	1.9	3
359	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
360	Dengue fever in a multiple sclerosis patient taking Ocrelizumab. Multiple Sclerosis Journal, 2021, 27, 135245852110302.	3.0	3

#	ARTICLE	IF	CITATIONS
361	Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITIONâ€•A 2-Year, Multicenter, Observational, Cohort Study. Brain Sciences, 2022, 12, 215.	2.3	3
362	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â€‰years. Multiple Sclerosis Journal, 2022, 28, 2137-2141.	3.0	3
363	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
364	Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC Medical Research Methodology, 2022, 22, .	3.1	3
365	Cognitive dysfunction in pediatric-onset multiple sclerosis. , 0, , 134-143.		2
366	The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis. , 0, , 244-252.		2
367	EXPOSURE TO INTERFERON-Î² THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A17.2-A17.	1.9	2
368	THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. European Neurology, 2016, 75, 4-8.	1.4	2
369	A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis. Scandinavian Journal of Rheumatology, 2018, 47, 336-337.	1.1	2
370	A Pilot Longitudinal Evaluation of MicroRNAs for Monitoring the Cognitive Impairment in Pediatric Multiple Sclerosis. Applied Sciences (Switzerland), 2020, 10, 8274.	2.5	2
371	Assessing long-term effectiveness of MS treatment â€" a matter of debate. Nature Reviews Neurology, 2021, 17, 197-198.	10.1	2
372	Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFNÎ²-1b treatment. Multiple Sclerosis Journal, 1998, 4, 183-187.	3.0	2
373	Real world comparison of teriflunomide and dimethyl fumarate in naÃ¯ve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Multiple Sclerosis and Related Disorders, 2022, 58, 103489.	2.0	2
374	Seizure medication and planned pregnancy: balancing the risks and outcomes. Expert Review of Neurotherapeutics, 2022, 22, 527-539.	2.8	2
375	Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. Journal of the Neurological Sciences, 1986, 73, 325-338.	0.6	1
376	Corrigendum to â€œLinkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeansâ€•[J. Neuroimmunol. 179 (2006) 108â€"116]. Journal of Neuroimmunology, 2007, 189, 175-176.	2.3	1
377	Improving combination trials for multiple sclerosis. Lancet Neurology, The, 2010, 9, 646-647.	10.2	1
378	The use of multiple population-based data sources for estimating MS sex ratio trends over time. Multiple Sclerosis Journal, 2014, 20, 1551-1552.	3.0	1

#	ARTICLE	IF	CITATIONS
379	Advances in the management of MS symptoms: real-life evidence. Neurodegenerative Disease Management, 2015, 5, 19-21.	2.2	1
380	The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta. Value in Health, 2015, 18, A754.	0.3	1
381	Environmental Factors and Their Regulation of Immunity in Multiple Sclerosis. , 2016, , 99-111.		1
382	PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL) Tj ETQq0 0 0 rgBT /Over	0.3	1
383	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. Journal of Neurology, 2019, 266, 3098-3107.	3.6	1
384	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing–Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). Frontiers in Neurology, 2021, 12, 637615.	2.4	1
385	Effectiveness and safety of ocrelizumab in a real-world setting: A single center experience from southern italy. Journal of the Neurological Sciences, 2021, 429, 117790.	0.6	1
386	Guillain–Barré syndrome associated with inappropriate secretion of antidiuretic hormone following SARS–CoV–2 infection: A case–report. Clinical Case Reports (discontinued), 2021, 9, e04667.	0.5	1
387	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110590.	1.0	1
388	Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review. Neurological Sciences, 2022, , 1.	1.9	1
389	Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate. Internal and Emergency Medicine, 2022, , 1.	2.0	1
390	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
391	Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. Neurological Sciences, 0, , .	1.9	1
392	IS IT TIME TO USE OBSERVATIONAL DATA TO ESTIMATE TREATMENT EFFECTIVENESS IN MULTIPLE SCLEROSIS?. Neurology, 2008, 71, 463-464.	1.1	0
393	Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Expert Review of Neurotherapeutics, 2013, 13, 1-1.	2.8	0
394	A rare case of multiple sclerosis and McArdle disease. Neurological Sciences, 2015, 36, 1721-1723.	1.9	0
395	085…Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri® observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	1.9	0
396	Novel Assessment of Real-world Effectiveness of Ocrelizumab for Treatment of Patients with Relapsing and Primary Progressive Multiple Sclerosis: Design of a Multicenter Non-interventional Study (musicale Study). Multiple Sclerosis and Related Disorders, 2018, 26, 256-257.	2.0	0

#	ARTICLE	IF	CITATIONS
397	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). Neurological Sciences, 2020, 41, 1881-1889.	1.9	0
398	Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients. Journal of the Neurological Sciences, 2021, 429, 117749.	0.6	0
399	Contribution of post marketing studies to define treatment strategies. Journal of the Neurological Sciences, 2021, 429, 117892.	0.6	0
400	Serum neurofilament light chain in a cohort of multiple sclerosis, MOG-antibody diseases and neuromyelitis optica spectrum disorders patients. Journal of the Neurological Sciences, 2021, 429, 117791.	0.6	0
401	Blood-CSF barrier permselectivity and measurement of intrathecal IgG synthesis in multiple sclerosis. , 1984, , 441-447.		0
402	Intrathecal IgG Synthesis in Multiple Sclerosis: Correlation with Clinical Parameters. , 1988, , 21-31.		0
403	Disease Duration, Relapse rate and Clinical Course in Multiple Sclerosis: Relation to IgG Production within the Blood Brain Barrier. , 1990, , 23-31.		0
404	Magnetic resonance imaging, proton magnetic resonance spectroscopy and cerebrospinal fluid abnormalities in multiple sclerosis. , 1996, , 123-132.		0
405	Synthesis Approaches to (â˜')-Cytoxazone, a Novel Cytokine Modulator, and Related Structures. , 2019, , 02-35.		0
406	A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-Î²1a in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 40, 101952.	2.0	0
407	Italian multiple sclerosis register as the basis for post-authorization safety studies. European Journal of Public Health, 2020, 30, .	0.3	0
408	023â€¦ Relapse outcomes with natalizumab Q4W vs switch to Q6W. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.3-A21.	1.9	0
409	Macular ganglion cell-inner plexiform layer defect patterns in multiple sclerosis patients without optic neuritis: A Spectral-Domain-Optical Coherence Tomography Cross-Sectional, Case-Control, Pilot Study. European Journal of Ophthalmology, 0, , 112067212211128.	1.3	0